Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Atropine drops for drooling: a randomized controlled trial.

Gustavo G De Simone1, Jorge H Eisenchlas, Marta Junin

  • 1Palliative Care Service, Hospital Bonorino Udaondo and Pallium Latinoamerica, Buenos Aires.

Palliative Medicine
|October 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gut-Brain Axis and Migraine: Rates of Improvement and Predictors of Response After a Low-FODMAP, Low-Starch and Low-Sucrose Dietary Intervention.

Journal of human nutrition and dietetics : the official journal of the British Dietetic Association·2025
Same author

Management of pain in cancer patients - an update.

Ecancermedicalscience·2025
Same author

Exploring the gut-brain axis in a large cohort of patients with irritable bowel syndrome: Is there a link between depression and intestinal and extra-intestinal symptoms?

Gastroenterologia y hepatologia·2025
Same author

Predictors of response to a dietary intervention in patients with irritable bowel syndrome.

Gastroenterologia y hepatologia·2024
Same author

Prevalence of extra-intestinal symptoms according to irritable bowel syndrome subtype.

Neurogastroenterology and motility·2024
Same author

New embracing approach for better advanced cancer patient comprehensive care.

Medicina·2023
Same journal

Understanding workplace peer support among healthcare assistants providing palliative and end-of-life care at home: A realist review.

Palliative medicine·2026
Same journal

Exploring Pathways to Optimise Care in malignant bowel obstruction (EPOC): A realist review of shared decision-making with people with advanced cancer and severe symptoms.

Palliative medicine·2026
Same journal

Caregivers' perspectives on family meetings and preparedness for imminent death: A qualitative descriptive study in a palliative care setting.

Palliative medicine·2026
Same journal

Palliative care: The holy grail of healthcare interventions?

Palliative medicine·2026
Same journal

Social determinants of death anxiety in patients with advanced cancer receiving outpatient palliative care.

Palliative medicine·2026
Same journal

A Reflexivity Lab as a methodological tool in end-of-life research.

Palliative medicine·2026
See all related articles

This study found sublingual atropine ineffective for reducing drooling in cancer patients. Further research is needed to explore alternative treatments for sialorrhoea and improve patient quality of life.

Area of Science:

  • Oncology
  • Gastroenterology
  • Palliative Care

Background:

  • Drooling (sialorrhoea) is a common issue in cancer patients, negatively impacting their quality of life.
  • Anticholinergic drugs are often recommended, but scientific evidence supporting their efficacy is limited.
  • Sublingual atropine has been explored, necessitating controlled studies to validate its use.

Purpose of the Study:

  • To assess the effectiveness of sublingual atropine compared to a placebo in managing drooling among upper digestive cancer patients.
  • To provide evidence-based insights into the treatment of sialorrhoea in this specific patient population.

Main Methods:

  • A prospective, randomized, double-blind, placebo-controlled, cross-over trial involving 22 cancer patients.
  • Patients received either atropine or placebo for 48 hours, followed by a 48-hour washout period and then crossed over.

Related Experiment Videos

  • Outcomes, including sialorrhoea severity and impact on daily activities, were measured using visual analogue scales (VAS).

    • Main Results:

    • No statistically significant difference was observed in sialorrhoea scores between atropine and placebo groups (P=0.58).
    • Secondary outcomes, such as choking and interference with daily activities, also showed no significant improvement with atropine.
    • The study reported no severe adverse events or toxicity associated with atropine use.

    Conclusions:

    • Sublingual atropine did not demonstrate superior effectiveness over placebo in alleviating drooling in patients with upper digestive cancer.
    • The findings suggest that atropine may not be an effective treatment for sialorrhoea in this patient group.
    • Further investigation into alternative or adjunctive therapies is warranted to manage drooling and enhance the quality of life for cancer patients.